CG Oncology (CGON)

• Market cap: $3.35B
• 1 day: 2.85%
• 5 days: 3.44%
• 1 month: -2.99%
• 3 months: 9.26%
• 6 months: 58.17%
• Year to date: -0.65%
• 1 year: 33.89%
• 5 years: 11.7%
• 10 years: 11.7%
• Sector: Healthcare
• Industry: Biotechnology

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113